Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer. - Phase II clinical study of nab-PTX for patients with recurrent NSCLC

The Japan-Multinational Trial Organization (JMTO)0 个研究点目标入组 81 人开始时间: 2015年3月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patient with previous treatment by paclitaxel. 2) Patient receiving chemotherapies less than 4 weeks or EGFR-TKI within two weeks. 3) Patient receiving definitive radiotherapy for less than 6 weeks or local palliative radiotherapy for less than 2 weeks. 4) Patient with symptomatic brain metastasis. 5) Patient with need of chest drainage for pleural effusion. 6) Active infection. 7) Patient with severe complications. 8) Patient having autoimmune disease to need treatment by the immunosuppressive drug. 9) Patient with active multiple cancers. 10) Female Patient in or having a chance or planning of pregnancy or breast feeding. Male patient in planning to impregnate. 11) History of sever psychological disease. 12) Administering steroid. 13) Any patients judged by the investigator to be unfit to participate in the study.

发起方

The Japan-Multinational Trial Organization (JMTO)